1. An update of nanoparticle-based approaches for glioblastoma multiforme immunotherapy
- Author
-
Lorenzo Taiarol, Silvia Sesana, Beatrice Formicola, Roberta Dal Magro, Francesca Re, Taiarol, L, Formicola, B, Magro, R, Sesana, S, and Re, F
- Subjects
brain ,medicine.medical_treatment ,Biomedical Engineering ,Medicine (miscellaneous) ,Bioengineering ,Development ,Bioinformatics ,blood–brain barrier, brain, drug delivery, drug delivery, glioblastoma multiforme, immunotherapy, nanomedicine, nanoparticles ,glioblastoma multiforme ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Medicine ,General Materials Science ,030304 developmental biology ,0303 health sciences ,Brain Neoplasms ,business.industry ,nanoparticle ,Immunotherapy ,blood-brain barrier ,medicine.disease ,nanomedicine ,Targeted drug delivery ,030220 oncology & carcinogenesis ,drug delivery ,Drug delivery ,Nanoparticles ,Nanomedicine ,immunotherapy ,Neoplasm Recurrence, Local ,Glioblastoma ,business ,Oncology field - Abstract
Glioblastoma multiforme is a serious medical issue in the brain oncology field due to its aggressiveness and recurrence. Immunotherapy has emerged as a valid approach to counteract the growth and metastasization of glioblastoma multiforme. Among the different innovative approaches investigated, nanoparticles gain attention because of their versatility which is key in allowing precise targeting of brain tumors and increasing targeted drug delivery to the brain, thus minimizing adverse effects. This article reviews the progress made in this field over the past 2 years, focusing on nonspherical and biomimetic particles and on vectors for the delivery of nucleic acids. However, challenges still need to be addressed, considering the improvement of the particles passage across the blood–meningeal barrier and/or the blood–brain barrier, promoting the clinical translatability of these approaches.
- Published
- 2020
- Full Text
- View/download PDF